The Alphabet Soup of HIV Reservoir Markers
- PMID: 28401492
- PMCID: PMC5519144
- DOI: 10.1007/s11904-017-0355-y
The Alphabet Soup of HIV Reservoir Markers
Abstract
Purpose of review: Despite the success of antiretroviral therapy in suppressing HIV, life-long therapy is required to avoid HIV reactivation from long-lived viral reservoirs. Currently, there is intense interest in searching for therapeutic interventions that can purge the viral reservoir to achieve complete remission in HIV patients off antiretroviral therapy. The evaluation of such interventions relies on our ability to accurately and precisely measure the true size of the viral reservoir. In this review, we assess the most commonly used HIV reservoir assays, as a clear understanding of the strengths and weaknesses of each is vital for the accurate interpretation of results and for the development of improved assays.
Recent findings: The quantification of intracellular or plasma HIV RNA or DNA levels remains the most commonly used tests for the characterization of the viral reservoir. While cost-effective and high-throughput, these assays are not able to differentiate between replication-competent or defective fractions or quantify the number of infected cells. Viral outgrowth assays provide a lower bound for the fraction of cells that can produce infectious virus, but these assays are laborious, expensive and substantially underestimate the potential reservoir of replication-competent provirus. Newer assays are now available that seek to overcome some of these problems, including full-length proviral sequencing, inducible HIV RNA assays, ultrasensitive p24 assays and murine adoptive transfer techniques. The development and evaluation of strategies for HIV remission rely upon our ability to accurately and precisely quantify the size of the remaining viral reservoir. At this time, all current HIV reservoir assays have drawbacks such that combinations of assays are generally needed to gain a more comprehensive view of the viral reservoir. The development of novel, rapid, high-throughput assays that can sensitively quantify the levels of the replication-competent HIV reservoir is still needed.
Keywords: Assays; Cure; HIV; QVOA; Replication-competent; Reservoir.
Similar articles
-
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.Annu Rev Immunol. 2000;18:665-708. doi: 10.1146/annurev.immunol.18.1.665. Annu Rev Immunol. 2000. PMID: 10837072 Review.
-
Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents.J Virol. 2017 Feb 28;91(6):e02296-16. doi: 10.1128/JVI.02296-16. Print 2017 Mar 15. J Virol. 2017. PMID: 28077644 Free PMC article.
-
Measuring HIV Persistence on Antiretroviral Therapy.Adv Exp Med Biol. 2018;1075:265-284. doi: 10.1007/978-981-13-0484-2_11. Adv Exp Med Biol. 2018. PMID: 30030797 Review.
-
Improved assays to measure and characterize the inducible HIV reservoir.EBioMedicine. 2018 Oct;36:113-121. doi: 10.1016/j.ebiom.2018.09.036. Epub 2018 Oct 11. EBioMedicine. 2018. PMID: 30316868 Free PMC article.
-
Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir.Retrovirology. 2018 Feb 13;15(1):21. doi: 10.1186/s12977-018-0404-7. Retrovirology. 2018. PMID: 29433524 Free PMC article. Review.
Cited by
-
The HIV-1 antibody response: a footprint of the viral reservoir in children vertically infected with HIV.Lancet HIV. 2020 May;7(5):e359-e365. doi: 10.1016/S2352-3018(20)30100-4. Lancet HIV. 2020. PMID: 32386722 Free PMC article. Review.
-
Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations.Curr HIV/AIDS Rep. 2021 Oct;18(5):475-482. doi: 10.1007/s11904-021-00569-8. Epub 2021 Jul 2. Curr HIV/AIDS Rep. 2021. PMID: 34213731 Free PMC article. Review.
-
Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART.JCI Insight. 2020 Mar 26;5(6):e134196. doi: 10.1172/jci.insight.134196. JCI Insight. 2020. PMID: 32097124 Free PMC article. Clinical Trial.
-
The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like.Front Immunol. 2019 Sep 20;10:2251. doi: 10.3389/fimmu.2019.02251. eCollection 2019. Front Immunol. 2019. PMID: 31616425 Free PMC article. Review.
-
VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies.mBio. 2021 Jun 29;12(3):e0056021. doi: 10.1128/mBio.00560-21. Epub 2021 Jun 22. mBio. 2021. PMID: 34154408 Free PMC article.
References
-
- Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512–7. - PubMed
-
- Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, Crooks AM, Parker DC, Anderson EM, Kearney MF, Strain MC, Richman DD, Hudgens MG, Bosch RJ, Coffin JM, Eron JJ, Hazuda DJ, Margolis DM. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487:482–5. - PMC - PubMed
-
- Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guergnon J, Viard J-P, Boufassa F, Lambotte O, Goujard C, Meyer L, Costagliola D, Venet A, Pancino G, Autran B, Rouzioux C, ANRS VISCONTI Study Group Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013;9:e1003211. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
